Lyell Immunopharma, Inc.

Ownership Transactions Reported by 19 Insiders

Symbol: LYEL on Nasdaq
Industry: Pharmaceutical Preparations
Location: 201 Haskins Way, South San Francisco, CA

There are no Buy or Sell transactions made by insiders since 3/4/2024

Lyell Immunopharma, Inc. executives and other stock owners filed with the SEC include:

Name	Relationship	Holdings Value	Past Year Net Change	Change %	Report Date
ARCH Venture Partners IX, LLC	10%+ Owner	$83M			Jun 21, 2021
Robert Nelsen	Director, 10%+ Owner	$83M			Jun 14, 2024
GSK plc	10%+ Owner	$69M			Jun 21, 2021
Hans Edgar Bishop	Director	$10.7M			Jun 14, 2024
Richard Klausner	Director	$8.33M			Jun 14, 2024
Cathy Friedman	Director	$767K			Jun 14, 2024
Lynn Seely	President and CEO, Director	$456K			Feb 10, 2025
Gary K. Lee	Chief Scientific Officer	$120K			Feb 10, 2025
Matthew Lang	Chief Business Officer	$114K			Feb 10, 2025
Stephen J. Hill	Chief Operating Officer	$112K			Feb 10, 2025
Charles W. Newton	Chief Financial Officer	$111K			Feb 10, 2025
Tina M. Albertson	Chief Medical Officer	$9.23K			Feb 24, 2023
Rahsaan Thompson	Chief Legal Officer				Feb 24, 2023
Heather D. Turner	Chief General Counsel				Mar 16, 2022
Elizabeth G. Nabel	Director				Jun 14, 2024
Otis W. Brawley	Director				Jun 14, 2024
William Jl Rieflin	Director				Jun 14, 2024
Elizabeth Homans	Chief Executive Officer, Director				Mar 16, 2022
Sumant Ramachandra	Director				Oct 31, 2024

Showing 1 to 19 of 19 entries

Recent Insider Transactions by Companies or Individuals for Lyell Immunopharma, Inc.

Insider	Symbol	Class	Transaction	%	Value $	* Price $	Shares	Shares Owned	Date	Ownership

* An asterisk sign (*) next to the price indicates that the price is likely invalid.